Compagnie Lombard Odier SCmA Buys 19,000 Shares of Incyte Co. (NASDAQ:INCY)

Compagnie Lombard Odier SCmA lifted its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 15,833.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,120 shares of the biopharmaceutical company's stock after purchasing an additional 19,000 shares during the quarter. Compagnie Lombard Odier SCmA's holdings in Incyte were worth $1,158,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Quintet Private Bank Europe S.A. bought a new position in shares of Incyte in the fourth quarter valued at $26,000. Raiffeisen Bank International AG bought a new stake in shares of Incyte during the 4th quarter worth about $34,000. Bradley & Co. Private Wealth Management LLC acquired a new position in Incyte in the 4th quarter valued at about $42,000. NBC Securities Inc. grew its stake in Incyte by 88,200.0% in the 1st quarter. NBC Securities Inc. now owns 883 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 882 shares during the last quarter. Finally, Huntington National Bank raised its holdings in Incyte by 40.7% in the 4th quarter. Huntington National Bank now owns 934 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 270 shares during the period. 96.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on INCY. Truist Financial lifted their target price on Incyte from $72.00 to $73.00 and gave the stock a "hold" rating in a report on Tuesday, May 27th. Wells Fargo & Company upped their target price on Incyte from $58.00 to $59.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Morgan Stanley dropped their price objective on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, March 24th. Guggenheim cut Incyte from a "buy" rating to a "neutral" rating and set a $92.00 target price for the company. in a report on Tuesday, March 18th. Finally, William Blair downgraded shares of Incyte from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $72.53.

Incyte Price Performance

Incyte stock traded down $1.47 during midday trading on Friday, reaching $67.75. 1,834,959 shares of the stock were exchanged, compared to its average volume of 2,086,033. Incyte Co. has a 52 week low of $53.56 and a 52 week high of $83.95. The company's fifty day moving average is $62.30 and its 200-day moving average is $67.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. The firm has a market cap of $13.11 billion, a PE ratio of 250.94, a PEG ratio of 0.41 and a beta of 0.67.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.15. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $996.17 million. Incyte had a net margin of 0.77% and a return on equity of 0.05%. The firm's revenue was up 19.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 EPS. On average, sell-side analysts forecast that Incyte Co. will post 4.86 EPS for the current year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.